A Modern Approach to Multiple Sclerosis Trials Applying Innovative Digital Endpoint Solutions

(Moderator) Todd Rudo, MD, EVP, Chief Medical Officer, Clario

Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety.

Dr. Rudo has board certifications in Cardiology, Cardiac Electrophysiology, Nuclear Cardiology, Adult Echocardiography and Internal Medicine. His team provides expert consulting to clients on scientific and regulatory strategy and ensures Clario’s product portfolio is scientifically robust, generating high-quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.

Laura Khurana, MPH, Senior Principal Scientific Advisor, eCOA Science & Consulting, Clario

Laura Khurana is an experienced public health and clinical research professional with a special interest in electronic clinical outcome assessments (eCOAs) for clinical trials. Laura has 17 years of experience in clinical research, initially working in web-based data collection for patient registries and post-approval safety studies. Laura has been at Clario for 10 years, and in her current role as Principal Scientific Advisor, she leads the scientific direction for eCOA services, including designing data collection strategies based on best practices, the literature, patient and site preferences and applicable regulations. She has experience supporting trials across a wide range of clinical indications, including multiple sclerosis, headache and migraine, dermatology and diabetes. Laura earned her MPH from Boston University School of Public Health and her BA from the University of Georgia.

Douglas Arnold MD, Professor, Department of Neurology & Neurosurgery, McGill University; President and CEO, NeuroRx; Senior Advisor, Clario

Dr. Douglas Arnold is a leading figure in multiple sclerosis research and neuroimaging, with a career spanning over three decades at the intersection of academic medicine and clinical innovation. He founded NeuroRx in 2002 to apply cutting-edge imaging science to global clinical trials. NeuroRx is now part of Clario, where Dr. Arnold serves as Senior Advisor.

A Professor at McGill University and a Distinguished James McGill Professor, Dr. Arnold has directed the MRI lab at the McConnell Brain Imaging Center since 1985. His academic credentials include Neurology training at the Montreal Neurological Institute and advanced MRI studies at the University of Oxford.

Dr. Arnold has authored more than 450 peer-reviewed publications and is among the top 1% of most-cited researchers worldwide. His work has significantly influenced MS treatment and imaging standards, with seminal studies featured in The New England Journal of Medicine and The Lancet. He continues to lead initiatives in AI-powered imaging and clinical trial optimization through his roles at NeuroRx and now Clario.

Vrutangkumar V. Shah, PhD, Director of Data Science and Biostatistics, Precision Motion, Clario

Dr. Vrutangkumar V. Shah is a Scientist with over 13 years of experience in clinical research. He is currently working as a Director, Data Science and Biostatistics at Clario, a global data and technology company that supports decentralized clinical trials. He consults with sponsors and CROs in developing the Statistical Analysis Plan (SAP) package for Phase I-IV clinical studies. His expertise includes, but is not limited to, data analytics, biostatistics, machine learning and time-series analysis for developing digital biomarkers for clinical trials.